NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Aprea Therapeutics, Inc. (APRE) Stock Analysis

Aprea Therapeutics, Inc. (APRE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

APRE

$0.56

−$0.00 (−0.16%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APRE with… →

APRE Key Statistics

As of Oct 21, 2026
Trading
Open
$0.56
Previous Close
$0.56
Day's Range
0.51–0.60
52-Week Range
0.51–1.57
Volume
81.57K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.63
Valuation
Market Cap
$7.05M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1,360.62
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.95
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$12.60M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
12.59M
1-Year Return
−62.89%
Dividend and dates
Avg Volume
292.02K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, APRE closed at $0.56, −62.89% over 1 year.

Aprea Therapeutics, Inc. (APRE) has a market capitalization of $7.05M.

In fiscal 2025, APRE reported revenue of $0.00.

APRE Stock Return by Calendar Year

Aprea Therapeutics, Inc. (APRE) return since Oct 2019: what $10,000 became

1 year
$10,000 $3,711
−62.89%
5 years
$10,000 $55
−99.45%
Since Oct 2019
$10,000 $14
−99.86%

If you had invested $10,000 in Aprea Therapeutics, Inc. (APRE) at the close on October 3, 2019, the earliest close on record here, it would have been worth $14 at the close on October 21, 2026: −99.86% in total, −60.76% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−34.31%
2025−74.07%
2024−30.00%
2023−29.00%
2022−88.47%
2021−41.67%
2020−89.28%
2019 (partial year)+123.85%

As of October 21, 2026.

APRE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$12.60M—
2024$0.00−$12.96M—
2023$0.00−$14.29M—
2022$0.00−$112.66M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$13.23M−$12.60M—
2024$0.00—−$14.32M−$12.96M—
2023$0.00—−$15.47M−$14.29M—
2022$0.00—−$37.37M−$112.66M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

APRE Valuation vs Biotechnology Median

Median of 608 stocks
MetricAPREBiotechnology medianvs median
P/S ratio1,360.6213.30102.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Aprea Therapeutics, Inc. (APRE) is capitalised at $7.05M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 8.

The most recent close on file for APRE is $0.56, dated October 21, 2026. That is $0.00 (−0.16%) against the previous close. Over the past 52 weeks the price has ranged from $0.51 to $1.57. The latest close sits 9.73% above that 52-week low.

Financial Health

In fiscal 2025, Aprea Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $12.60M. Earnings per share on a trailing basis come to −0.95.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 1,360.62 times revenue. On price-to-sales that is 102.3 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.63. Annualized volatility over the trailing 7 years is 624.65%. Over the trailing twelve months the total return is −62.89%. Measured over 5 years, that is −64.70% a year compounded.

Growth & Income

No dividend is on file for APRE.

2026 is still running; the total return is −34.31% year to date. The strongest complete calendar year on file is 2023 at −29.00%; the weakest is 2020 at −89.28%. Of the 6 complete calendar years on file, 0 finished higher.

Peer Comparison

Aprea Therapeutics, Inc. (APRE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aprea Therapeutics, Inc. APRE $7.05M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Aprea Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Visit website →